It is time to drop euphemisms like DNA medicines and gene-based medicines. Gene therapy, says Nuala Moran, has made it through to the commercial mainstream.
Europe has staked its future on building a knowledge economy. But once again, a major R&D investment by one of its leading companies is going to the US.
In a rare example of a university tec transfer deal attracting an upfront payment, French pharma company Ipsen paying €1.25 million for a treatment licence.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.